Mirum Pharmaceuticals Dirección

Dirección controles de criterios 2/4

El CEO de Mirum Pharmaceuticals es Chris Peetz , nombrado en Mar 2019, tiene una permanencia de 5.67 años. compensación anual total es $6.45M, compuesta por 10.2% salario y 89.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.6% de las acciones de la empresa, por valor de MX$244.69M. La antigüedad media del equipo directivo y de la junta directiva es de 3.7 años y 4.3 años, respectivamente.

Información clave

Chris Peetz

Chief Executive Officer (CEO)

US$6.5m

Compensación total

Porcentaje del salario del CEO	10.2%
Permanencia del CEO	5.7yrs
Participación del CEO	0.6%
Permanencia media de la dirección	3.7yrs
Promedio de permanencia en la Junta Directiva	4.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chris Peetz en comparación con los beneficios de Mirum Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$100m
Jun 30 2024	n/a	n/a	-US$109m
Mar 31 2024	n/a	n/a	-US$159m
Dec 31 2023	US$6m	US$660k	-US$163m
Sep 30 2023	n/a	n/a	-US$164m
Jun 30 2023	n/a	n/a	-US$176m
Mar 31 2023	n/a	n/a	-US$129m
Dec 31 2022	US$4m	US$624k	-US$136m
Sep 30 2022	n/a	n/a	-US$42m
Jun 30 2022	n/a	n/a	-US$53m
Mar 31 2022	n/a	n/a	-US$70m
Dec 31 2021	US$4m	US$600k	-US$84m
Sep 30 2021	n/a	n/a	-US$179m
Jun 30 2021	n/a	n/a	-US$153m
Mar 31 2021	n/a	n/a	-US$132m
Dec 31 2020	US$3m	US$512k	-US$103m
Sep 30 2020	n/a	n/a	-US$84m
Jun 30 2020	n/a	n/a	-US$78m
Mar 31 2020	n/a	n/a	-US$68m
Dec 31 2019	US$6m	US$458k	-US$53m
Sep 30 2019	n/a	n/a	-US$61m
Dec 31 2018	US$385k	US$32k	-US$26m

Compensación vs. Mercado: La compensación total de Chris($USD6.45M) está por encima de la media de empresas de tamaño similar en el mercado MX ($USD702.78K).

Compensación vs. Ingresos: La compensación de Chris ha aumentado mientras la empresa no es rentable.

CEO

Chris Peetz (45 yo)

5.7yrs

Permanencia

US$6,451,720

Compensación

Mr. Christopher Peetz, also known as Chris, serves as Entrepreneur-in-Residence at Frazier Management, L.L.C since May 30, 2017. He also serves as Entrepreneur-in-Residence at Frazier Life Sciences Managem...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Christopher Peetz	CEO & Director	5.7yrs	US$6.45m	0.60% MX$ 244.7m
Peter Radovich	COO & President	4.6yrs	US$2.37m	0.042% MX$ 17.0m
Eric Bjerkholt	Chief Financial Officer	1.2yrs	US$4.69m	0.069% MX$ 28.2m
Pamela Vig	Chief Scientific Officer	less than a year	US$1.51m	0.19% MX$ 78.5m
Andrew McKibben	Vice President of Investor Relations and Finance	no data	sin datos	sin datos
Paul Ross	Chief Compliance Officer	4.6yrs	sin datos	sin datos
Erin Campany	Senior Vice President of Human Resources	5.8yrs	sin datos	sin datos
Lara Longpre	Chief Development Officer	5.9yrs	US$1.51m	0.20% MX$ 80.2m
Vinita Kumar	Senior vice President of Quality	2.8yrs	sin datos	sin datos
Jean-Luc Girardet	Senior Vice President of Technical Operations	1.8yrs	sin datos	sin datos
Joanne M. Quan	Chief Medical Officer	less than a year	sin datos	0.00025% MX$ 101.7k
Jolanda Howe	Senior VP & Global Controller	no data	sin datos	0.0050% MX$ 2.1m

3.7yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MIRM * se considera experimentado (3.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Christopher Peetz	CEO & Director	no data	US$6.45m	0.60% MX$ 244.7m
Patrick Heron	Independent Director	6yrs	US$401.75k	0% MX$ 0
Laura Brege	Independent Director	5.3yrs	US$426.75k	0.021% MX$ 8.5m
Michael Grey	Independent Non-Executive Chairman of the Board	5.7yrs	US$451.75k	0.58% MX$ 237.4m
Laurent Fischer	Independent Director	5.4yrs	US$421.75k	0.014% MX$ 5.7m
Timothy Walbert	Independent Director	1.6yrs	US$671.53k	0% MX$ 0
Sona Saira Ramasastry	Independent Director	2.4yrs	US$411.75k	sin datos
William Fairey	Independent Director	3.3yrs	US$411.75k	0% MX$ 0
Lon Cardon	Independent Director	2yrs	US$194.47k	0% MX$ 0

4.3yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de MIRM * se considera experimentada (4.3 años de antigüedad promedio).

Mirum Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Mirum Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Mirum Pharmaceuticals, Inc. Announces Management Changes

Mirum Pharmaceuticals, Inc. Announces Management Appointments

President recently sold Mex$2.5m worth of stock

Mirum Pharmaceuticals, Inc. Appoints Eric Bjerkholt as the Chief Financial Officer

Mirum Pharmaceuticals, Inc. Announces Resignation of Ian Clements as Chief Financial Officer

Recent updates

Third quarter 2024 earnings released: US$0.30 loss per share (vs US$0.57 loss in 3Q 2023)

Mirum Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Mirum Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Volixibat in Treating Cholestatic Pruritus in PBC

Mirum Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Mirum Pharmaceuticals, Inc’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Olderer

Mirum Pharmaceuticals, Inc.' LIVMARLI Approves in the European Union for Patients with PFIC

Forecast breakeven date pushed back to 2026

Mirum Pharmaceuticals Announces Positive Chmp Opinion for Livmarli® (Maralixibat) Oral Solution for the Treatment of Pfic in Patients Three Months of Age and Older

Mirum Pharmaceuticals, Inc Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC

Mirum Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Mirum Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada’S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome

Mirum Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approve LIVMARLI (Maralixibat) Oral Solution for the Treatment of Cholestatic Pruritus in Patients Five Years of Age and Older with Progressive Familial Intrahepatic Cholestasis

Mirum Pharmaceuticals, Inc. announced delayed annual 10-K filing

Mirum Pharmaceuticals, Inc. Provides Sales Guidance for the Year 2024

Mirum Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Mirum Pharmaceuticals, Inc. Announces Management Changes

Mirum Pharmaceuticals, Inc. Announces Management Appointments

President recently sold Mex$2.5m worth of stock

Mirum Pharmaceuticals, Inc. Provides Earnings Guidance for Fourth Quarter 2023 and Full Year 2023

Mirum Pharmaceuticals, Inc. Announces Data from EMBARK Phase 2b Study for Biliary Atresia

Forecast breakeven date pushed back to 2025

Mirum Pharmaceuticals, Inc. Presents New Data at the Liver Meeting

Mirum Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Mirum Pharmaceuticals, Inc. Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

Mirum Pharmaceuticals, Inc. Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN

Mirum Pharmaceuticals, Inc. Announces Positive Phase 3 Restore Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis

Mirum Pharmaceuticals, Inc. Appoints Eric Bjerkholt as the Chief Financial Officer

Mirum Pharmaceuticals, Inc. (NasdaqGM:MIRM) completed the acquisition of Bile Acid Product Portfolio from Travere Therapeutics, Inc. (NasdaqGM:TVTX).

Mirum Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Mirum Pharmaceuticals's LIVMARLI Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome

Mirum Pharmaceuticals, Inc. announced that it expects to receive $210 million in funding from Frazier Life Sciences Management, LP, Avidity Partners Management, L.P., BVF Partners L.P., Longitude Capital Management Co., LLC, Sofinnova Investment, Inc. and another investor

Mirum Pharmaceuticals, Inc. Showcases Five New LIVMARLI (maralixibat) Presentations at the EASL Congress

Mirum Pharmaceuticals, Inc. Announces Data from It's LIVMARLI Studies Presented at ESPGHAN Annual Meeting

Mirum Pharmaceuticals, Inc. Announces Hepatology Communications Publishes Data from CAMEO Study Evaluating Safety, Tolerability, and Efficacy of LIVMARLI® (Maralixibat) Oral Solution in Patients with Primary Sclerosing Cholangitis

Mirum Pharmaceuticals, Inc. Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia Study

Forecast to breakeven in 2025

Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

Forecast to breakeven in 2025

Mirum Pharmaceuticals, Inc. Announces Resignation of Ian Clements as Chief Financial Officer

Mirum Pharmaceuticals, Inc. Announces Resignation of Carol L. Brosgart, M.D. as A Director of the Company and as A Member of the Nominating and Corporate Governance Committee of the Board, Effective December 19, 2022

Mirum Pharmaceuticals, Inc. Appoints Lon Cardon to Board of Directors

Mirum Pharmaceuticals, Inc. Announces LIVMARLI (maralixibat) Approval by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older

Mirum Pharmaceuticals Provides Development Program Updates

Forecast to breakeven in 2024

Mirum Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Mirum Pharmaceuticals, Inc. Reports Positive Topline Data from Its Phase 3 March Study

Mirum Pharmaceuticals, Inc. Announces Positive Topline Results from Its Pivotal Phase 3 March Study Evaluating Livmarli

Mirum Pharmaceuticals’ announces LIVMARLI Data Highlighting Quality of Life and Sleep Improvements in Patients with Alagille Syndrome Published in Journal of Pediatrics

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and Older

No longer forecast to breakeven

Mirum Pharmaceuticals, Inc. Announces Resignation of Edward T. Mathers as A Member of the Compensation Committee of the Board, Effective September 1, 2022

Mirum Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Forecast to breakeven in 2024

Mirum Pharmaceuticals, Inc.(NasdaqGM:MIRM) dropped from Russell Microcap Value Index

Mirum Pharmaceuticals Highlights Data Demonstrating Impact of Livmarli® (Maralixibat) on Patients with Alagille Syndrome

Mirum Pharmaceuticals, Inc. Appoints Saira Ramasastry to the Board of Directors and as A Member of the Audit Committee

Forecast to breakeven in 2024

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad